Evidence map›Paper›PMID 40687654›Full record

ArticleTranslational andrology and urology2025

Interpretable machine learning driven biomarker identification and validation for prostate cancer.

Jianxu Yuan, Dalin Zhou, Shengjie Yu

Abstract read
In one paragraph

Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jianxu YuanDepartment of Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, Chongqing, China.ORCID https://orcid.org/0000-0003-0963-6008
Dalin ZhouDepartment of Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, Chongqing, China.
Shengjie YuDepartment of Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, Chongqing, China.ORCID https://orcid.org/0009-0001-5634-0763

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Prostate cancer (PCa), a common malignancy among men globally, requires the identification of biomarkers for early diagnosis and predicting progression. This study aimed to identify the key genes involved in the occurrence and development of PCa. Methods: Leveraging data from the Gene Expression Omnibus (GEO) database, this study integrated multi-chip datasets, conducting differential expression analysis and enrichment analysis to pinpoint PCa-related genes. Subsequently, machine learning models were constructed using least absolute shrinkage and selection operator (LASSO) regression, support vector machine (SVM), and random forest (RF) methods. The optimal model was selected for further study and the contribution of related genes was explained using SHapley Additive exPlanations (SHAP) analysis. Furthermore, gene set enrichment analysis (GSEA) and immune cell infiltration analysis were utilized to uncover the underlying molecular mechanisms. Results: In this study, 222 differentially expressed genes (DEGs) were identified and found to be enriched in functions and pathways potentially associated with PCa. Using multiple machine learning models, eight PCa-related core genes ( Conclusions: This study offered potential biomarkers and a theoretical basis for the diagnosis and treatment for PCa.

Indexed as

least absolute shrinkage and selection operator regression (LASSO regression)Prostate cancer (PCa)random forest (RF)SHapley Additive exPlanations (SHAP)support vector machine (SVM)

Identifiers

PMID40687654
PMCPMC12271943

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.